Research programme: factor IXa inhibitors - TrigenAlternative Names: Factor IXa inhibitors research programme - Trigen
Latest Information Update: 16 Apr 2010
At a glance
- Originator Trigen Holdings AG
- Class Small molecules
- Mechanism of Action Factor IXa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Feb 2008 This programme is still in active development
- 03 Aug 2005 This programme is still in active development - (BIO-2005)
- 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG